Log In
Print this Print this

Synriam, arterolane maleate/piperaquine phosphate

  Manage Alerts
Collapse Summary General Information
Company Sun Pharmaceutical Industries Ltd.
Description150 mg arterolane maleate and 750 mg piperaquine phospate
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentMarketed
Standard IndicationMalaria
Indication DetailsTreat malaria caused by Plasmodium Vivax; Treat malaria in adults
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today